D.E. Shaw & Co
SEEL

D.E. Shaw & Co’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

D.E. Shaw & Co’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-30
Closed -$276K – 5786
2021
Q3 		$276K Buy
30
+6
+25% +$51.6K ﹤0.01% 4406
2021
Q2 		$247K Buy
+24
New +$394K ﹤0.01% 4365

Other funds holding SEEL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

D.E. Shaw & Co's SEEL Position: Q4 2021 in Review

D.E. Shaw & Co sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2021, closing a stake of 30 shares — an estimated $276K sold.

D.E. Shaw & Co first reported a position in SEEL in Q2 2021 and held it in 2 quarters. The position peaked at $276K in Q3 2021. 82 funds tracked by Wall St. Rank hold SEEL as of Q4 2021.

  • D.E. Shaw & Co reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • D.E. Shaw & Co sold 30 Seelos Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $276K.
  • D.E. Shaw & Co first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • D.E. Shaw & Co's Seelos Therapeutics, Inc. Common Stock position peaked at $276K in Q3 2021.
  • 82 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2021.

Based on D.E. Shaw & Co's 13F filing for Q4 2021, filed 14 Feb 2022.